Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT01522976)
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (294 Sites)
Showing the first 25 of 294 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
- Mayo Clinic in Arizona — Scottsdale, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- John L McClellan Memorial Veterans Hospital — Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Kaiser Permanente-Oakland — Oakland, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- Kaiser Permanente-Richmond — Richmond, California
- Kaiser Permanente-South Sacramento — Sacramento, California
- Kaiser Permanente Sacramento Medical Center — Sacramento, California
- Kaiser Permanente-San Francisco — San Francisco, California
- Kaiser Permanente-Santa Teresa-San Jose — San Jose, California
- Kaiser Permanente-San Rafael — San Rafael, California
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara, California
- Kaiser Permanente-Santa Rosa — Santa Rosa, California
- Sutter Pacific Medical Foundation — Santa Rosa, California
- Kaiser Permanente-South San Francisco — South San Francisco, California
- Kaiser Permanente-Vallejo — Vallejo, California
- Kaiser Permanente-Walnut Creek — Walnut Creek, California
- The Medical Center of Aurora — Aurora, Colorado
- UCHealth University of Colorado Hospital — Aurora, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Myelomonocytic Leukemia
- Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion — Tampa, Florida
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes — Houston, Texas
- Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia — Houston, Texas
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed — Los Angeles, California
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm — Phoenix, Arizona
Explore by condition: All Chronic Myelomonocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.